Last 1,489 INR
Change Today -14.00 / -0.93%
Volume 671.5K
LPC On Other Exchanges
Natl India
As of 6:06 AM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

lupin ltd (LPC) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/15 - 1,524
52 Week Low
01/30/14 - 855.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LUPIN LTD (LPC)

Related News

No related news articles were found.

lupin ltd (LPC) Related Businessweek News

No Related Businessweek News Found

lupin ltd (LPC) Details

Lupin Limited, a pharmaceutical company, produces, develops, and markets a range of branded and generic formulations and active pharmaceutical ingredients (APIs) primarily in India, the United States, and Japan. It offers various formulations for use in the areas of cephalosporin, cardiovascular (CVS), central nervous system (CNS), anti-asthma, anti-tuberculosis, diabetology, dermatology, gastro intestinal, and other therapy segments; and APIs for use in therapeutic areas of antibiotics, anti-tuberculosis, CVS, CNS, analgesics, and anti-gout. The company also develops and out-licenses its drug delivery technologies and platforms; and creates and develops biosimilars for various therapeutic indications, such as oncology, inflammation, antivirals, osteoporosis, and rheumatoid arthritis. In addition, it is engaged in the novel drug discovery and development programs for use in the treatment of metabolic disorders, pain and inflammation, autoimmune diseases, CNS disorders, cancer, and infectious diseases. Lupin Limited has a strategic partnership with Merck Serono S.A. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

15,000 Employees
Last Reported Date: 05/7/14
Founded in 1968

lupin ltd (LPC) Top Compensated Officers

Founder, Chairman, Member of Share Transfer C...
Total Annual Compensation: 31.8M
Managing Director and Executive Director
Total Annual Compensation: 52.4M
Executive Director, Member of Share Transfer ...
Total Annual Compensation: 3.6M
Compensation as of Fiscal Year 2014.

lupin ltd (LPC) Key Developments

Jubilant Life Sciences, Aurobindo and Lupin Receive US FDA Approval to Produce Generic Versions of Novartis' Diovan Hypertension Treatment

Jubilant Life Sciences, Aurobindo and Lupin Pharmaceutical - have received final US FDA approval to produce a generic equivalent of Novartis' (Switzerland) Diovan (valsartan) drug, which is indicated for the treatment of hypertension, blood pressure and heart failure. Israel's Teva also recently announced its intention to launch a generic version of Diovan. Lupin pharmaceutical and Jubilant have announced that they are ready to launch valsartan on the US market in strengths of 40 mg, 80 mg 160 mg and 320 mg.

Lupin Limited Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 02:30 PM

Lupin Limited Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 02:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Vinita Gupta, Chief Executive Officer, Executive Director, Chief Executive Officer of Lupin Pharmacuticls Inc Usa and Group President of Lupin Pharmacuticls Inc Usa.

Lupin Receives FDA Approval for Darunavir Ethanolate Tablets

Lupin Limited announced that it has received tentative approval for its Darunavir Ethanolate Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg and 800 mg from the United States Food and Drugs Administration to market a generic version of Janssen Products, LP (Janssen) Prezista Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg. Lupin's Darunavir Ethanolate Tablets 75 mg, 150 mg, 300 mg, 400 mg, 600 mg are the AB-rated generic equivalents of Janssen's Prezista tablets and are indicated Lupin's Darunavir Tablets is indicated for the treatment of HIV-1 infections.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPC:IN 1,489.45 INR -14.00

LPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $69.81 USD +0.81
H Lundbeck A/S kr131.50 DKK +3.10
Ipca Laboratories Ltd 638.80 INR -60.15
Piramal Enterprises Ltd 834.95 INR +5.30
Salix Pharmaceuticals Ltd $125.92 USD -0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation LPC Industry Range
Price/Earnings 29.5x
Price/Sales 5.3x
Price/Book 8.2x
Price/Cash Flow 25.5x
TEV/Sales 5.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUPIN LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at